Le Lézard
Classified in: Covid-19 virus
Subject: Funding

Sheridan Capital Partners Fund II Closes Above Hard Cap on $306 Million of Capital

Sixpoint Partners, a leading global investment bank serving the middle market, announced today the successful closing of Sheridan Capital Partners Fund II, L.P. (together with its parallel fund, "Fund II" or the "Fund"), above the hard cap with $306 million of total capital commitments.

The Fund experienced outsized demand despite the headwinds of COVID-19, with total capital commitments significantly in excess of the $250 million target and more than double the size of its predecessor. Sheridan Capital Partners ("Sheridan") is focused on making investments in lower middle market companies in recession resistant, non-discretionary markets within the healthcare industry. The Fund will continue Sheridan's strategy of making control investments in North American founder-owned businesses with $3-15 million of EBITDA. Sheridan is led by Partners Jonathan Lewis and Sean Dempsey.

"We are extremely pleased with the overwhelming support provided by our investor base, which encompasses a high-quality group of internationally diversified insurance companies, fund-of-funds, family offices and asset managers," stated Jonathan Lewis, Founder & Partner at Sheridan.

"Sixpoint Partners' continued strategic advice and support throughout the process were instrumental in the successful outcome of the fundraise," said Sean Dempsey, Partner at Sheridan.

"Sheridan's oversubscribed sophomore fundraise in a highly selective environment shows a strong vote of confidence in Jonathan, Sean and the rest of the Sheridan team," said Eric Zoller, Founder & Partner at Sixpoint Partners.

"Sheridan has established itself as a leader in the lower middle market healthcare space and we look forward to a long-term partnership as they continue to generate value for their investors by building differentiated, market-leading platforms within lower middle market healthcare," said Matt Thornton, Partner at Sixpoint Partners.

About Sheridan Capital Partners

Sheridan Capital Partners is a Chicago-based healthcare private equity firm that focuses on lower middle market buyouts and growth equity in the U.S. and Canada. Sheridan partners with companies in the verticals of providers and provider services, healthcare IT and outsourced services, and consumer health and medical products, bringing strategic resources to accelerate growth, build enduring value, and achieve strong results. www.sheridancp.com

About Sixpoint Partners

Sixpoint Partners is a leading global investment bank focused on delivering strategic advisory and fundraising solutions for the middle-market private equity industry. The firm's core areas of focus include (i) primary fund placement and strategic advisory, (ii) secondaries advisory and (iii) co-investment placement across a wide range of industries, strategies and geographies. Sixpoint Partners has a reputation for its direct, results-driven style and for delivering innovative solutions to complex problems in order to create long-term value for clients. Sixpoint is headquartered in New York with offices in Chicago, San Francisco and London. Investment banking and other advisory activities are provided by Sixpoint Partners LLC ("Sixpoint") a registered broker-dealer and a member of FINRA and SIPC. For more information, please visit www.sixpointpartners.com.

These press releases may also interest you

at 03:22
Yiling Pharmaceutical's business income in 2020 hits 8.736 billion yuan (USD 1.35 billion) with an increase of 49.97% YoY, and the net profit reaches 1.220 billion yuan (USD 189 million), 101.12% YoY growth, according to the Annual Performance...

at 02:20
It's a new beginning for Big...

at 02:18
The Teamsters are applauding the House's passage of a $1.9 trillion COVID-19 stimulus bill today that includes language granting relief to hundreds of endangered multiemployer pension plans that would protect the hard-earned retirements of more than...

26 fév 2021
The LaunchPorttm announced today that Novel Microdevices (http://www.noveldx.com) has moved to their Medtech venture center in Port Covington, Baltimore, and has established The LaunchPorttm as its primary location for their GMP development efforts....

26 fév 2021
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Sorrento Therapeutics, Inc. . On May 15, 2020, news sources...

26 fév 2021
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Inovio Pharmaceuticals Inc. . On March 9, 2020 Citron Research...

News published on 19 january 2021 at 07:20 and distributed by: